IN2007DN02514A - - Google Patents

Info

Publication number: IN2007DN02514A
Authority: IN; India

Application number

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-26

Filing date

2005-10-26

Publication date

2007-08-03

2005-10-26 Application filed filed Critical

2007-08-03 Publication of IN2007DN02514A publication Critical patent/IN2007DN02514A/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Addiction (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Anesthesiology (AREA)
Psychology (AREA)
Child & Adolescent Psychology (AREA)

IN2514DEN2007 2004-10-26 2005-10-26 IN2007DN02514A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US62250804P	2004-10-26	2004-10-26
US67267005P	2005-04-18	2005-04-18
PCT/US2005/038361 WO2006047516A2 (en)	2004-10-26	2005-10-26	Compounds and compositions as inhibitors of cannabinoid receptor 1 activity

Publications (1)

Publication Number	Publication Date
IN2007DN02514A true IN2007DN02514A (en)	2007-08-03

Family

ID=36228382

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN2514DEN2007 IN2007DN02514A (en)	2004-10-26	2005-10-26

Country Status (20)

Country	Link
US (2)	US8158634B2 (en)
EP (1)	EP1807429A4 (en)
JP (2)	JP2008518016A (en)
KR (1)	KR100919524B1 (en)
CN (2)	CN101048408B (en)
AR (1)	AR051596A1 (en)
AU (2)	AU2005299421B2 (en)
BR (1)	BRPI0517015A (en)
CA (2)	CA2730374A1 (en)
EC (1)	ECSP077421A (en)
IL (1)	IL182527A0 (en)
IN (1)	IN2007DN02514A (en)
MA (1)	MA28937B1 (en)
MX (1)	MX2007004936A (en)
NO (1)	NO20072352L (en)
PE (1)	PE20060599A1 (en)
RU (1)	RU2431635C2 (en)
TN (1)	TNSN07161A1 (en)
TW (1)	TW200630096A (en)
WO (1)	WO2006047516A2 (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20050696B1 (en)	2003-01-14	2008-10-31	Arena Pharmaceuticals Inc.	1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US7132426B2 (en)	2003-07-14	2006-11-07	Arena Pharmaceuticals, Inc.	Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
JP2007519754A (en) *	2004-01-30	2007-07-19	スミスクラインビーチャムコーポレーション	Compound
AR051596A1 (en) *	2004-10-26	2007-01-24	Irm Llc	CONDENSED HETEROCICLIC COMPOUNDS NITROGENATED AS INHIBITORS OF THE ACTIVITY OF THE CANABINOID RECEIVER 1; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPLOYMENT IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF FOOD DISORDERS
GB0506147D0 (en) *	2005-03-24	2005-05-04	Merck Sharp & Dohme	Therapeutic agents
WO2006122200A1 (en) *	2005-05-11	2006-11-16	Merck Sharp & Dohme Limited	2,3-substituted fused bicyclic pyrimidin-4(3h)-ones modulating the function of the vanilloid-1 receptor (vr1)
US20090163521A1 (en) *	2005-06-28	2009-06-25	Orchid Research Laboratories Limited	Novel Pyrazolopyrimidinone Derivatives
AU2006311883A1 (en)	2005-11-04	2007-05-18	Hydra Biosciences, Inc.	Compounds for modulating TRPV3 function
US8022075B2 (en)	2005-11-30	2011-09-20	Fujifilm Ri Pharma Co., Ltd.	Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
ES2388881T3 (en)	2006-03-30	2012-10-19	Irm Llc	Azolopyrimidines as inhibitors of cannabinoid activity 1
EP2061767B1 (en)	2006-08-08	2014-12-17	Sanofi	Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
AU2007288203B2 (en)	2006-08-23	2013-01-17	Neurogen Corporation	2-phenoxy pyrimidinone analogues
WO2008134300A1 (en) *	2007-04-26	2008-11-06	Irm Llc	Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2008140750A1 (en)	2007-05-10	2008-11-20	Hydra Biosciences Inc.	Compounds for modulating trpv3 function
JP5485148B2 (en) *	2007-06-21	2014-05-07	カラセラピューティクスインコーポレイテッド	Substituted imidazo heterocycles
EP2025674A1 (en)	2007-08-15	2009-02-18	sanofi-aventis	Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
BRPI0817211A2 (en)	2007-09-20	2017-05-16	Irm Llc	compound compositions as modulators of gpr119 activity
WO2009079593A1 (en) *	2007-12-17	2009-06-25	Janssen Pharmaceutica N.V.	Piperazinyl derivatives useful as modulators of the neuropeptide y2 receptor
US8686158B2 (en) *	2008-06-05	2014-04-01	President And Fellows Of Harvard College	High-valent palladium fluoride complexes and uses thereof
US8470841B2 (en)	2008-07-09	2013-06-25	Sanofi	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
US8324385B2 (en)	2008-10-30	2012-12-04	Madrigal Pharmaceuticals, Inc.	Diacylglycerol acyltransferase inhibitors
US9024093B2 (en)	2008-11-20	2015-05-05	President And Fellows Of Harvard College	Fluorination of organic compounds
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011014520A2 (en)	2009-07-29	2011-02-03	Irm Llc	Compounds and compositions as modulators of gpr119 activity
CN102482312A (en)	2009-08-26	2012-05-30	赛诺菲	Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
CN102686579A (en)	2009-10-09	2012-09-19	Irm责任有限公司	Compounds and compositions as modulators of GPR119 activity
EP2582709B1 (en)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8697739B2 (en)	2010-07-29	2014-04-15	Novartis Ag	Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
MX2013003184A (en)	2010-09-22	2013-06-07	Arena Pharm Inc	Modulators of the gpr119 receptor and the treatment of disorders related thereto.
EP2683702B1 (en)	2011-03-08	2014-12-24	Sanofi	New substituted phenyl oxathiazine derivatives, method for their manufacture, medicines containing these compounds and their application
WO2012120053A1 (en)	2011-03-08	2012-09-13	Sanofi	Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8901114B2 (en)	2011-03-08	2014-12-02	Sanofi	Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8846666B2 (en)	2011-03-08	2014-09-30	Sanofi	Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683699B1 (en)	2011-03-08	2015-06-24	Sanofi	Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683705B1 (en)	2011-03-08	2015-04-22	Sanofi	Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120051A1 (en)	2011-03-08	2012-09-13	Sanofi	Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120056A1 (en)	2011-03-08	2012-09-13	Sanofi	Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683703B1 (en)	2011-03-08	2015-05-27	Sanofi	Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
KR101326557B1 (en) *	2011-03-31	2013-11-08	주식회사종근당	Benzamide derivatives as cannabinoid cb1 receptor antagonists
WO2012142162A2 (en) *	2011-04-12	2012-10-18	President And Fellows Of Harvard College	Fluorination of organic compounds
TW201311689A (en)	2011-08-05	2013-03-16	必治妥美雅史谷比公司	Novel macrocyclic compounds as factor XIA inhibitors
US9067943B2 (en) *	2011-11-25	2015-06-30	Hoffmann-La Roche Inc.	[1,2,3]triazolo[4,5-D]pyrimidine derivatives
WO2014052622A1 (en)	2012-09-26	2014-04-03	President And Fellows Of Harvard College	Nickel fluorinating complexes and uses thereof
WO2014052619A1 (en)	2012-09-27	2014-04-03	Irm Llc	Piperidine derivatives and compositions as modulators of gpr119 activity
JP6514119B2 (en) *	2013-03-07	2019-05-15	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Novel pyrazole derivative
JP6479763B2 (en)	2013-03-25	2019-03-06	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Substituted azole containing tetrahydroisoquinolines as factor XIA inhibitors
PE20151977A1 (en)	2013-05-02	2016-01-07	Hoffmann La Roche	NEW PURINE DERIVATIVES
KR20160002857A (en)	2013-05-02	2016-01-08	에프. 호프만-라 로슈 아게	Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
KR20220140651A (en)	2013-09-06	2022-10-18	에프. 호프만-라 로슈 아게	Novel triazolo[4,5-d]pyrimidine derivatives
US10759764B2 (en)	2013-10-18	2020-09-01	President And Fellows Of Harvard College	Fluorination of organic compounds
US11007175B2 (en)	2015-01-06	2021-05-18	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the S1P1 receptor
TW201702247A (en)	2015-04-17	2017-01-16	艾伯維有限公司	Indazolones as modulators of TNF signaling
AR104291A1 (en)	2015-04-17	2017-07-12	Abbvie Inc	TRICYCLIC MODULATORS OF TNF SIGNALING
TW201706258A (en)	2015-04-17	2017-02-16	艾伯維有限公司	Indazolones as modulators of TNF signaling
BR112017027656B1 (en)	2015-06-22	2023-12-05	Arena Pharmaceuticals, Inc.	CRYSTALLINE HABIT OF SALT-FREE PLATE OF ACID L-ARGININE (R)-2-(7-(4- CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)- 1,2,3,4-TETRA-HYDROCYCLO-PENTA[B ]INDOL-3- IL)ACETIC, PHARMACEUTICAL COMPOSITION THAT COMPRISES IT, ITS USES AND METHOD OF PREPARATION THEREOF
JP6746679B2 (en) *	2015-07-23	2020-08-26	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	Compound
EP3471712B1 (en) *	2016-06-20	2024-01-03	The Regents of The University of Michigan	Small molecule inhibitors of aldh and uses thereof
WO2018013430A2 (en)	2016-07-12	2018-01-18	Arisan Therapeutics Inc.	Heterocyclic compounds for the treatment of arenavirus infection
WO2018049214A1 (en)	2016-09-09	2018-03-15	Incyte Corporation	Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
UA125650C2 (en)	2016-09-09	2022-05-11	Інсайт Корпорейшн	HPK1 REGULATORS BASED ON PYRAZOLOPYRIDINE DERIVATIVES AND THEIR APPLICATIONS FOR CANCER TREATMENT
AR109595A1 (en)	2016-09-09	2018-12-26	Incyte Corp	PIRAZOLOPIRIMIDINE COMPOUNDS AND USES OF THESE AS HPK1 INHIBITORS
CN106632069A (en) *	2016-11-18	2017-05-10	山东友帮生化科技有限公司	Method for synthesizing 3-chloro-6-hydrazinopyridazine
US20180228786A1 (en)	2017-02-15	2018-08-16	Incyte Corporation	Pyrazolopyridine compounds and uses thereof
CA3053418A1 (en)	2017-02-16	2018-08-23	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of primary biliary cholangitis
WO2019051199A1 (en)	2017-09-08	2019-03-14	Incyte Corporation	6-cyano-indazole compounds as hematopoietic progenitor kinase 1 (hpk1) modulators
US10745388B2 (en)	2018-02-20	2020-08-18	Incyte Corporation	Indazole compounds and uses thereof
HRP20220833T1 (en)	2018-02-20	2022-10-28	Incyte Corporation	N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer
WO2019164847A1 (en)	2018-02-20	2019-08-29	Incyte Corporation	Indazole compounds and uses thereof
US11299473B2 (en)	2018-04-13	2022-04-12	Incyte Corporation	Benzimidazole and indole compounds and uses thereof
BR112020024762A2 (en)	2018-06-06	2021-03-23	Arena Pharmaceuticals, Inc.	methods of treating conditions related to the s1p1 receptor
US10899755B2 (en)	2018-08-08	2021-01-26	Incyte Corporation	Benzothiazole compounds and uses thereof
TW202028207A (en)	2018-09-25	2020-08-01	美商英塞特公司	Pyrazolopyrimidine compounds and uses thereof
US12419865B2 (en)	2018-12-06	2025-09-23	Arisan Therapeutics Inc.	Compounds for the treatment of arenavirus infection
MX2022001562A (en)	2019-08-06	2022-04-26	Incyte Corp	SOLID FORMS OF AN INHIBITOR OF HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1).
HUE071972T2 (en)	2020-01-29	2025-10-28	Kamari Pharma Ltd	Compounds and compositions for use in treating skin disorders
KR102584607B1 (en) *	2023-01-19	2023-10-04	아주대학교산학협력단	Composition for Preventing or Treating Inflammatory Skin Diseases Comprising 1H-Pyrazole-3-Amide Compound Derivatives

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2631139B2 (en) *	1988-10-06	1997-07-16	ライオン株式会社	1H-pyrazolo [3,4-b] pyrazine derivative
KR0151816B1 (en)	1994-02-08	1998-10-15	강박광	Novel substituted pyridyl imidazole derivatives and preparation methods thereof
CA2417156A1 (en)	2000-08-01	2003-01-23	Ono Pharmaceutical Co., Ltd.	3,4-dihydroisoquinoline derivative compound and a pharmaceutical agent comprising it as active ingredient
AU2002214546A1 (en) *	2000-09-29	2002-04-08	Cor Therapeutics, Inc.	Bicyclic pyrimidin-4-one based inhibitors of factor xa
CN100348599C (en) *	2002-06-06	2007-11-14	卫材R&D管理有限公司	Novel fused imidazole derivatives
CA2494091C (en) *	2002-08-02	2011-02-01	Richard B. Toupence	Substituted furo [2,3-b\| pyridine derivatives
EP1553947A4 (en)	2002-10-21	2006-11-29	Bristol Myers Squibb Co	Quinazolinones and derivatives thereof as factor xa inhibitors
US7129239B2 (en)	2002-10-28	2006-10-31	Pfizer Inc.	Purine compounds and uses thereof
US20040242566A1 (en) *	2003-03-25	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
US7141669B2 (en)	2003-04-23	2006-11-28	Pfizer Inc.	Cannabiniod receptor ligands and uses thereof
US7638530B2 (en) *	2003-04-24	2009-12-29	Merck & Co., Inc.	Inhibitors of Akt activity
AU2004290626A1 (en) *	2003-11-14	2005-06-02	Merck Sharp & Dohme Limited	Bicyclic pyrimidin-4-(3H)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (VR1)
AR051596A1 (en) *	2004-10-26	2007-01-24	Irm Llc	CONDENSED HETEROCICLIC COMPOUNDS NITROGENATED AS INHIBITORS OF THE ACTIVITY OF THE CANABINOID RECEIVER 1; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPLOYMENT IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF FOOD DISORDERS

2005
- 2005-10-24 AR ARP050104440A patent/AR051596A1/en not_active Application Discontinuation
- 2005-10-25 TW TW094137369A patent/TW200630096A/en unknown
- 2005-10-25 PE PE2005001251A patent/PE20060599A1/en not_active Application Discontinuation
- 2005-10-26 EP EP05813001A patent/EP1807429A4/en not_active Withdrawn
- 2005-10-26 US US11/718,016 patent/US8158634B2/en not_active Expired - Fee Related
- 2005-10-26 CN CN2005800368900A patent/CN101048408B/en not_active Expired - Fee Related
- 2005-10-26 BR BRPI0517015-0A patent/BRPI0517015A/en not_active IP Right Cessation
- 2005-10-26 CN CN2011101210450A patent/CN102241680A/en active Pending
- 2005-10-26 JP JP2007539039A patent/JP2008518016A/en not_active Withdrawn
- 2005-10-26 WO PCT/US2005/038361 patent/WO2006047516A2/en not_active Ceased
- 2005-10-26 MX MX2007004936A patent/MX2007004936A/en not_active Application Discontinuation
- 2005-10-26 CA CA2730374A patent/CA2730374A1/en not_active Abandoned
- 2005-10-26 CA CA2581225A patent/CA2581225C/en not_active Expired - Fee Related
- 2005-10-26 RU RU2007119449/04A patent/RU2431635C2/en not_active IP Right Cessation
- 2005-10-26 IN IN2514DEN2007 patent/IN2007DN02514A/en unknown
- 2005-10-26 AU AU2005299421A patent/AU2005299421B2/en not_active Ceased
2007
- 2007-04-12 IL IL182527A patent/IL182527A0/en unknown
- 2007-04-18 MA MA29834A patent/MA28937B1/en unknown
- 2007-04-25 TN TNP2007000161A patent/TNSN07161A1/en unknown
- 2007-04-25 KR KR1020077009370A patent/KR100919524B1/en not_active Expired - Fee Related
- 2007-04-26 EC EC2007007421A patent/ECSP077421A/en unknown
- 2007-05-07 NO NO20072352A patent/NO20072352L/en not_active Application Discontinuation
2009
- 2009-12-24 AU AU2009251216A patent/AU2009251216A1/en not_active Abandoned
2011
- 2011-06-22 JP JP2011138840A patent/JP2011190281A/en active Pending
2012
- 2012-03-08 US US13/415,565 patent/US20120225869A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN102241680A (en)	2011-11-16
WO2006047516A2 (en)	2006-05-04
WO2006047516A3 (en)	2006-10-12
MA28937B1 (en)	2007-10-01
TW200630096A (en)	2006-09-01
CA2730374A1 (en)	2006-05-04
AU2005299421A1 (en)	2006-05-04
KR100919524B1 (en)	2009-10-01
NO20072352L (en)	2007-05-31
KR20070057980A (en)	2007-06-07
PE20060599A1 (en)	2006-08-22
RU2431635C2 (en)	2011-10-20
AR051596A1 (en)	2007-01-24
AU2009251216A1 (en)	2010-01-28
RU2007119449A (en)	2008-12-10
CA2581225A1 (en)	2006-05-04
EP1807429A2 (en)	2007-07-18
JP2011190281A (en)	2011-09-29
US8158634B2 (en)	2012-04-17
US20120225869A1 (en)	2012-09-06
JP2008518016A (en)	2008-05-29
TNSN07161A1 (en)	2008-11-21
IL182527A0 (en)	2007-09-20
US20090247517A1 (en)	2009-10-01
EP1807429A4 (en)	2010-03-24
CN101048408B (en)	2011-07-06
ECSP077421A (en)	2007-05-30
BRPI0517015A (en)	2008-09-30
AU2005299421B2 (en)	2010-01-28
CA2581225C (en)	2011-10-25
CN101048408A (en)	2007-10-03
MX2007004936A (en)	2007-06-25

Publication	Publication Date	Title
BE2024C508I2 (en)	2024-08-08
BE2023C542I2 (en)	2025-02-07
BE2022C549I2 (en)	2024-08-08
BE2021C001I2 (en)	2025-02-11
BE2020C513I2 (en)	2024-08-08
BE2020C517I2 (en)	2024-08-08
BE2019C523I2 (en)	2025-02-10
BE2019C548I2 (en)	2024-10-09
BE2019C506I2 (en)	2025-04-23
BE2018C045I2 (en)	2024-08-08
BE2020C525I2 (en)	2025-02-11
BE2017C063I2 (en)	2025-02-07
BE2017C027I2 (en)	2024-08-08
BE2017C023I2 (en)	2024-08-08
BE2017C002I2 (en)	2024-08-08
BE2016C067I2 (en)	2024-08-08
BE2016C014I2 (en)	2024-10-09
BE2015C041I2 (en)	2024-10-08
BE2015C038I2 (en)	2019-10-23
BE2015C014I2 (en)	2024-08-08
BE2014C071I2 (en)	2024-10-08
BE2015C015I2 (en)	2025-04-29
BE2014C064I2 (en)	2024-08-08
BE2014C063I2 (en)	2024-08-08
BE2014C010I2 (en)	2024-08-08